James Molloy

Edward Woo

Gene Carter

- Ascendiant Capital Markets has maintained a **"Buy" rating** on IGC Pharma's stock and raised its price target from **$4.25 to $4.50**.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- IGC Pharma is a **clinical-stage biotechnology firm** developing cannabinoid-based treatments for Alzheimer’s disease, with its lead asset **IGC-AD1** currently in a Phase 2 trial.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- The company's pipeline includes other investigational drugs and it integrates **AI to accelerate drug discovery** and clinical trials.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- Analysts expect **positive clinical data and progress in 2025** to be strong catalysts for the stock.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- IGC Pharma has filed **30 patents** and demonstrates strong liquidity with a current ratio of **1.25**, a quick ratio of **0.47**, and a low debt-to-equity ratio of **0.02**.  **[1326205_92898fe448084552a83c7195b75b2cb6]**

IGC Pharma (IGC)